CARY, N.C., Dec. 14, 2022 Biologics by McKesson, an independent specialty pharmacy focused on oncology and rare disease areas, has been selected by Mirati therapeutics as one of two specialty pharmacies in a limited distribution network for KRAZATI® (adagrasib), which is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation as determined by an FDA-approved test, and who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification of a clinical benefit in a confirmatory trial.

KRAZATI, approved by the U.S. Food and Drug Administration (FDA) on December 12, 2022, is an orally administered, small molecule inhibitor, intentionally designed to meet the challenges of KRASG12C. KRAZATI was approved through the FDA’s Breakthrough Therapy Designation, which is designed to expedite drugs to market that are expected to have a significant impact on a disease’s treatment.

“Patients with KRAS mutations have limited treatment options, and the KRASG12C biomarker is associated with poor survival outcomes,” said Ela Lourido, vice president of Biopharma Services at Biologics. “We are honored to be selected by Mirati to bring a new therapeutic option to these patients.”

Biologics specialty pharmacy is committed to and recognized for its level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients. This deeply skilled care team works together to develop individualized care plans that address each patient’s unique clinical, financial, and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes.

For more information about the symptoms, diagnosis, and treatment of advanced non-small cell lung cancer harboring the KRASG12C mutation following prior systemic therapy, please click here to visit the product website. For more information about KRAZATI, including full prescribing information, please click here.


About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers, and biopharma, so together, they can deliver better care and outcomes for every patient.